Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Immunogenicity Study of IVACFLU-A/H5N1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adult 18 through 60 years of age at the enrollment visit.~* Literate (by self-report) and willing to provide written informed consent.~* Healthy adults, as established by the medical history and screening evaluations, including physical examination, capable and willing to complete Diary Cards, and willing to return for all follow-up visits.~* For females able to become pregnant, willing to utilize reliable birth control measures (intrauterine device, hormonal contraception, condoms) through the Day 43 visit.~Exclusion Criteria:~* Participation in another clinical trial involving any vaccine or therapy within the previous three months, or planned enrollment in such a trial during the period of this study.~* Received any non-study vaccine within 4 weeks prior to enrollment or refused to postpone receipt of such vaccines until after the Day 43 visit.~* Current or recent (within 2 weeks of enrollment) acute illness with or without fever.~* Received immune globulin or other blood products within 3 months prior to study enrollment or planned receipt of such products prior to the Day 43 visit.~* Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment. (For corticosteroids, this meant prednisone or equivalent, 0.5 mg per kg per day; topical or intranasal steroids were allowed.)~* History of asthma.~* Hypersensitivity after previous administration of any vaccine.~* Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein, antibiotics, and rubber (from the vaccine vial stoppers).~* Acute or chronic clinically significant pulmonary, cardiovascular, hepatobiliary, metabolic, neurologic, psychiatric, or renal functional abnormality, as determined by medical history, physical examination, or clinical laboratory screening tests (Phase 2 only), which in the opinion of the investigator, might have interfered with the study objectives.~* History of any blood or solid organ cancer.~* History of thrombocytopenic purpura or known bleeding disorder.~* History of seizures.~* Known or suspected immunosuppressed or immune deficient condition of any kind.~* Known Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection by self-report (Phase 3) or a positive test for either HBV surface antigen (HBsAg) or HCV antibody using anti-HCV test (Phase 2).~* Known HIV infection (self-report)~* Known active tuberculosis or symptoms of active tuberculosis (self-report).~* History of chronic alcohol abuse and/or illegal drug use.~* Pregnancy or lactation (a negative pregnancy test was required before administration of study product for all women of childbearing potential).~* History of Guillain-Barre Syndrome.~* Any condition in the opinion of the investigator that would have increased the health risk of the subject if he/she participated in the study or interfered with the evaluation of the study objectives.~Note: Minor out-of-range laboratory values no greater than Grade 1 were not considered to be exclusionary at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Phase 2: Placebo (Type: PLACEBO_COMPARATOR): Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
- Phase 2: Vaccine (15 mcg) (Type: ACTIVE_COMPARATOR): Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
- Phase 2: Vaccine (30 mcg) (Type: ACTIVE_COMPARATOR): Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
- Phase 3: Placebo (Type: PLACEBO_COMPARATOR): Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
- Phase 3: Vaccine (Type: EXPERIMENTAL): Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).